Endokrynologia Polska最新文献

{"title":"Emphysematous cystitis: an uncommon and severe complication of diabetes.","authors":"Krzysztof Nowakowski, Justyna Czarniecka, Stanisław Hartabus, Grzegorz Michno, Andrzej Potyka","doi":"10.5603/ep.108928","DOIUrl":"https://doi.org/10.5603/ep.108928","url":null,"abstract":"<p><p>Not required for Clinical Vignette.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"77 1","pages":"87-88"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147501317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipidogram profiles in patients with Graves' and Basedow's disease with and without orbitopathy.","authors":"Mariusz Nowak, Wojciech Nowak, Magdalena Londzin-Olesik, Bogdan Marek, Beata Kos-Kudła, Dariusz Kajdaniuk, Lucyna Siemińska, Jacek Karpe, Tomasz Wielkoszyński","doi":"10.5603/ep.108188","DOIUrl":"10.5603/ep.108188","url":null,"abstract":"<p><strong>Introduction: </strong>Researchers reported on the pathogenic role of hypercholesterolemia in thyroid orbitopathy (TO) and the use of statins in its prevention and treatment. To confirm these observations, we conducted a prospective study of patients with Graves' and Basedow's disease (GBD) to evaluate the relationship between the presence of TO and levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), and apolipoproteins A1 and B (Apo A1, Apo B), along with the impact of immunosuppressive treatment on the lipid profile.</p><p><strong>Material and methods: </strong>Forty-seven patients with GBD diagnosed within the past 12 months were eligible for the study. In the GBD group, 31 patients were diagnosed with active TO and qualified for immunosuppressive treatment, while 16 patients did not have TO. TC, TG, HDL-C, and LDL-C levels were measured in serum using enzymatic methods, and Apo A-1 and Apo B levels were determined by immunoturbidimetric methods.</p><p><strong>Results: </strong>The mean TC concentration in patients with active TO who qualified for immunosuppressive treatment was 207.7 ± 42.7 mg/dL, significantly higher than the values in GBD patients without TO symptoms (191.5 ± 47.8 mg/dL). After completing immunosuppressive treatment, the mean TC concentration increased to 214.3 ± 49.8 mg/dL, remaining significantly higher than before treatment. The mean LDL-C concentration in patients with active TO was 131.6 ± 40.4 mg/dL and was higher, though not significantly, compared to the GBD group without TO symptoms (122.6 ± 49.0 mg/dL). After immunosuppressive treatment, the mean LDL-C levels increased to 142.1 ± 54.5 mg/dL and were also significantly higher than before treatment. Additionally, the mean Apo B concentration in patients with active TO was significantly higher than in patients without TO. After immunosuppressive treatment, the mean Apo B concentration increased and remained significantly higher than before treatment. There was no significant difference in HDL-C, Apo A1, and TG concentrations between the groups with and without TO, nor their levels after immunosuppressive treatment.</p><p><strong>Conclusions: </strong>The use of statins as adjunctive therapy in GBD patients with active TO qualified for immunosuppressive treatment is reasonable due to the increase in TC, LDL-C, and Apo B levels during treatment, as well as for their pleiotropic effects, including their anti-inflammatory effects.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"11-19"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146230340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asprosin, but not subfatin, associated with non-obese polycystic ovary syndrome.","authors":"Reha Baran, Suzan Tabur, Seyithan Taysı, Esma Gülsun Arslan Cellat","doi":"10.5603/ep.108447","DOIUrl":"10.5603/ep.108447","url":null,"abstract":"<p><strong>Introduction: </strong>Polycystic ovary syndrome (PCOS) is a condition characterized by chronic hormonal and metabolic disturbances, commonly presenting with amenorrhea, hirsutism, and multiple ovarian cysts. Asprosin and subfatin are adipokines synthesized by adipose tissue and are associated with metabolic disorders. This study aimed to investigate these adipokines in normal-weight women with PCOS.</p><p><strong>Material and methods: </strong>A total of 60 normal-weight women were recruited in the study, including 30 diagnosed with PCOS according to the Rotterdam criteria and 30 healthy controls. Serum samples were collected on the third day of the menstrual cycle after an overnight fast in the morning. Demographic, metabolic, and hormonal parameters of the participants were subsequently analyzed.</p><p><strong>Results: </strong>In the PCOS group, levels of homeostatic model assessment of insulin resistance (HOMA-IR) index, insulin, asprosin, total testosterone, and Ferriman-Gallwey score were significantly higher compared with the control group. No significant difference was found in subfatin levels between the groups. Correlation analysis showed positive associations of asprosin with weight, body mass index (BMI), waist circumference, insulin, HOMA-IR, and C-reactive protein (CRP). In addition, receiver operating characteristic (ROC) analysis identified an asprosin cut-off value of 39.25 ng/mL, which yielded an area under the curve (AUC) of 0.760 [95% confidence interval (CI): 0.641-0.879], with a sensitivity of 66.7% and a specificity of 73.3% (p = 0.001). Furthermore, binary logistic regression analysis revealed that the plasma asprosin level was significantly correlated with PCOS in a model after controlling for age, BMI, and HOMA-IR [odds ratio (OR): 1.036, 95% CI: 1.000-1.073; p = 0.048], suggesting that asprosin could be an independent risk factor for PCOS.</p><p><strong>Conclusions: </strong>Asprosin, but not subfatin, was significantly elevated in non-obese women with PCOS. It may serve as a marker of PCOS independent of insulin resistance in normal-weight women.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"45-50"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146230345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pituitary carcinoma: a diagnostic labyrinth in a rare endocrinopathy.","authors":"Julia Anita Tarnowska, Filip Szydzik, Bartosz Żegleń, Ewa Zalewska, Monika Berendt-Obołończyk, Sonia Kaniuka-Jakubowska, Michał Kunc, Joanna Kufel-Grabowska, Renata Świątkowska-Stodulska","doi":"10.5603/ep.108399","DOIUrl":"https://doi.org/10.5603/ep.108399","url":null,"abstract":"","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"77 2","pages":"124-125"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147792886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early serum estradiol decline as a predictive biomarker of spontaneous abortion without fetal chromosomal abnormalities.","authors":"Yu-Han Shen, Sui Peng, Jiayi Li, Lei Shi, Yi-Xiao He, Ting Zhu, Ming-Jie Shen","doi":"10.5603/ep.106766","DOIUrl":"10.5603/ep.106766","url":null,"abstract":"<p><strong>Introduction: </strong>Identifying reliable biomarkers to predict spontaneous abortion (SA), particularly in pregnancies without fetal chromosomal abnormalities, remains a critical objective in obstetric care. This retrospective cohort study assessed the predictive utility of serum β-human chorionic gonadotropin (β-hCG), estradiol, and progesterone concentrations in patients experiencing SA with confirmed chromosomally normal chorionic villi.</p><p><strong>Material and methods: </strong>A retrospective analysis was conducted on clinical and laboratory data from 76 patients who experienced SA between 5 and 10 weeks of gestation and received care at the Department of Obstetrics and Gynecology of our hospital between 2019 and 2024. All patients underwent uterine evacuation, and chorionic villus specimens were assessed for chromosomal abnormalities using next-generation sequencing (NGS). Based on NGS findings, two groups were defined: patients without fetal chromosomal abnormalities [n = 36; defined as no structural variants > 0.1 megabase pairs (Mb)] and patients with fetal chromosomal abnormalities (n = 40; variants > 1 Mb). An additional control group (n = 100) with uncomplicated, ongoing pregnancies was included for comparison. Serum concentrations of βhCG, estradiol, and progesterone were measured and compared across groups in the pregnant women.</p><p><strong>Results: </strong>Peak serum β-hCG concentrations were significantly lower in the SA group without chromosomal abnormalities compared to both the chromosomally abnormal SA group and the control group. Similarly, peak progesterone and estradiol concentrations were lowest in the SA group without chromosomal abnormalities (p < 0.05). Among the three biomarkers, estradiol demonstrated the highest discriminatory capacity. A significantly higher rate of early serum estradiol decline was observed in the SA group without chromosomal abnormalities compared to the group with abnormalities (p = 0.027). In contrast, no significant differences were found in the rate of progesterone decline across the groups. The median estradiol concentration at the time of initial decline was also significantly lower in the SA group without chromosomal abnormalities than in the other two groups.</p><p><strong>Conclusion: </strong>Early decline in serum estradiol levels may serve as a superior biomarker for predicting SA not associated with fetal chromosomal abnormalities. In contrast, serum β-hCG and progesterone concentrations exhibited limited predictive value in this context. These findings support consideration of serum estradiol monitoring to facilitate timely clinical intervention in pregnancies at increased risk for non-chromosomal miscarriage.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"37-44"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146230363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare false-positive uptake: orbital conjunctival cyst mimicking metastasis on post-therapeutic radioiodine scan in thyroid cancer.","authors":"Ruiguo Zhang, Hui Wang, Wei Zheng, Peng Wang, Qiang Jia","doi":"10.5603/ep.108455","DOIUrl":"10.5603/ep.108455","url":null,"abstract":"<p><p>Not required for Clinical Vignettes.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"85-86"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146230258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Body mass index as a predictor of metabolic dysfunction‑associated steatotic liver disease - insights from the Polish Gallstone Surgery Registry.","authors":"Gerard Stupecki, Dorota Krzos, Łukasz Nawacki, Magdalena Kołomańska, Robert Mazurkiewicz, Marcin Niżnik, Krzysztof Ratnicki, Małgorzata Czerniak, Piotr Myrcha, Sebastian Lenarcik, Kryspin Mitura, Małgorzata Pajer, Laura Kacprzak, Piotr Richter, Maciej Sroczyński, Iwona Gorczyca-Głowacka","doi":"10.5603/ep.108313","DOIUrl":"https://doi.org/10.5603/ep.108313","url":null,"abstract":"<p><strong>Introduction: </strong>The relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and overweight/obesity, as well as prediabetes or type 2 diabetes mellitus (T2DM), is complex. It is known that these conditions increase the risk of MASLD. The aim of this study was to assess the influence of body mass index (BMI), sex, and prediabetes/T2DM status on the prevalence of MASLD.</p><p><strong>Material and methods: </strong>The study included patients from The Polish Gallstone Surgery Registry, and MASLD was diagnosed according to current criteria.</p><p><strong>Results: </strong>Among the 3392 participants, 859 (25.3%) had normal body mass, 1302 (38.4%) were overweight, and 1231 (36.3%) had obesity. MASLD was diagnosed in 828 patients (24.4%), including 93 (11%) with normal body mass, 280 (21.4%) who were overweight, and 455 (36.9%) with obesity, p < 0.001. The odds ratios (ORs) for MASLD increased from overweight [OR = 2.30, 95% confidence interval (CI): 1.62-3.30] to obesity class I (OR = 4.50, 95% CI: 3.16-6.50), obesity class II (OR = 7.91, 95% CI: 5.11-12.33), and obesity class III (OR = 12.74, 95% CI: 7.11-22.93), with p < 0.001 for all categories. The risk of MASLD occurrence increased with BMI in obesity class III and was OR = 4.70, 95% CI: 2.08-10.64, p = 0.02 in males and OR = 5.32, 95% CI: 2.91-9.71, p < 0.001 in females. For patients without T2DM or prediabetes, the risk of MASLD in obesity class III was nearly 9-fold higher [hazard ratio (HR): 8.77, 95% CI: 5.28-14.58, p = 0.001], compared with HR = 2.85, 95% CI: 1.43-5.68, p = 0.003 for those with T2DM or prediabetes.</p><p><strong>Conclusions: </strong>A significant association was demonstrated between the prevalence of MASLD and increasing BMI, and this relationship was more pronounced in women. T2DM/prediabetes had a predominant influence on the occurrence of MASLD. Both patients with excess body weight and, especially, patients with T2DM/prediabetes require mandatory MASLD diagnostics.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"77 1","pages":"51-61"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147501325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comprehensive analysis of the impact of low AMH on ART outcomes in young patients.","authors":"Asena Ayar Madenli, Gonul Ozer, Sevinc Ozmen","doi":"10.5603/ep.108916","DOIUrl":"10.5603/ep.108916","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the study was to investigate the value of anti-Müllerian hormone (AMH) as a predictor of implantation and/or clinical pregnancy rate per started intracytoplasmic sperm injection (ICSI) cycle in a young patient population with decreased versus normal ovarian reserve.</p><p><strong>Material and methods: </strong>This retrospective case-control cohort study utilized data extracted from participants' electronic medical records. Patients were subsequently grouped into AMH < 1.1 [decreased ovarian reserve group (DOR)] and AMH ≥ 1.1 [normal ovarian reserve group (NOR)]. The groups were organized to be age-compatible to evaluate specifically the role of AMH in the outcomes. Prediction performance was examined with receiver operating characteristic (ROC) curves.</p><p><strong>Results: </strong>A total of 716 women were analyzed, including 298 (41.6%) with diminished ovarian reserve (DOR) and 418 age-matched women with normal ovarian reserve (NOR) serving as controls (58.4%). AMH levels below 1.1 ng/mL and 0.47 ng/mL were associated with an increased likelihood of embryo transfer (ET) cancellation. Among women who proceeded to ET, higher AMH levels were associated with positive implantation (all p < 0.001). An AMH cut-off value of ≥ 1.1 ng/mL significantly predicted clinical pregnancy and live birth, and overall AMH levels were significantly higher in women who achieved ET, implantation, clinical pregnancy, and live birth than in those who did not (all p < 0.001).</p><p><strong>Conclusions: </strong>Higher AMH levels were associated with better ET, implantation, and clinical pregnancy, especially in NOR patients; however, we also showed that the rates of pregnancy outcomes after the development of a transferable embryo in younger cases are similar to those in cases with NOR. Low but not severely diminished AMH levels in young patients may not necessarily indicate poor oocyte quality.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"29-36"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146230229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meacham syndrome in a patient with gonadal dysgenesis, congenital cardiac malformations, and short stature.","authors":"Elżbieta Moszczyńska, Oliwia Miszczuk, Marta Baszyńska-Wilk","doi":"10.5603/ep.109886","DOIUrl":"https://doi.org/10.5603/ep.109886","url":null,"abstract":"","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"77 2","pages":"122-123"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147792833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypercalcemia in hospitalized patients: prevalence, etiology and mortality predictors in a tertiary internal medicine ward.","authors":"Ertunç Şimdi, Mehmet Uzunlulu, Erhan Eken, İlksen Gönenç Komutan, Uğur Gökçe, Fatma Bayır Yetkin, Ekin Koç, Merve Gülin Yener, Bünyamin Akça, Aylin Gedik, Furkan Bal, Maher El Janabi","doi":"10.5603/ep.108400","DOIUrl":"10.5603/ep.108400","url":null,"abstract":"<p><strong>Introduction: </strong>Hypercalcemia is a potentially life-threatening electrolyte disorder with diverse etiologies and clinical manifestations, frequently encountered in hospitalized patients. Understanding its prevalence, causes, and associated outcomes in the inpatient setting is crucial for improving patient management and prognosis. The objectives were to determine the prevalence, etiological distribution, clinical and demographic characteristics, comorbidities, laboratory features, and mortality risk factors of hypercalcemia among patients admitted to an internal medicine clinic in a tertiary university hospital.</p><p><strong>Material and methods: </strong>This retrospective, observational cohort study included adults (≥ 18 years) hospitalized with hypercalcemia (corrected calcium ≥ 10.2 mg/dL, confirmed twice at least 24 hours apart) between January 2022 and January 2024. Hypercalcemia severity was classified as mild, moderate, or severe. Etiological categories included malignancy-associated, endocrine-related, vitamin D-mediated, other, and undetermined. Demographics, comorbidities, laboratory parameters, treatments, and outcomes were recorded. Univariate and multivariate analyses were performed to identify mortality risk factors.</p><p><strong>Results: </strong>Among 3,157 admissions, 190 patients (prevalence 6%) had confirmed persistent hypercalcemia (mean age 72.3 ± 13.1 years; 61.6% female). Malignancy was the leading cause (49.5%), followed by other causes (24.7%), undetermined (15.8%), endocrine (8.4%), and vitamin D-mediated (1.6%). Severe hypercalcemia (11.6%) was predominantly associated with malignancy. Overall in-hospital mortality was 24.2%, with male sex, malignancy, solid tumors, elevated aspartate aminotransferase (AST), hypoalbuminemia, and age 65-80 years independently associated with mortality. Survival was significantly worse in malignancy-related cases. The optimal parathyroid hormone (PTH) threshold for predicting malignancy was identified as ≤ 12.61 pg/mL. This cut-off demonstrated a sensitivity of 71.4% and a specificity of 91.3%.</p><p><strong>Conclusions: </strong>Hypercalcemia in hospitalized patients is predominantly associated with malignancy and advanced age, and is linked with high mortality. Early identification of risk factors and etiology-driven management are critical for improving outcomes.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"20-28"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146230394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}